Literature DB >> 14570735

Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C.

T Asselah1, N Boyer, M-C Guimont, D Cazals-Hatem, F Tubach, K Nahon, H Daïkha, D Vidaud, M Martinot, M Vidaud, C Degott, D Valla, P Marcellin.   

Abstract

BACKGROUND: In chronic hepatitis C, it has been suggested that steatosis could accelerate progression of fibrosis. However, results of the few published studies are controversial. AIM: To determine the characteristics (epidemiological, biological, and histological) associated with steatosis and its relationship with liver lesions (grade of necroinflammation and stage of fibrosis) in patients with chronic hepatitis C.
METHODS: From November 2000 to July 2001, untreated consecutive adults with chronic hepatitis C admitted for liver biopsy were included in this study. On the day of liver biopsy, a questionnaire for risk factors was completed prospectively, and a blood sample was obtained for laboratory analysis.
RESULTS: Our study included 290 patients (143 men, 147 women). Mean body mass index (BMI) was 24 (3.8) kg/m(2). Proportions of patients with genotypes 1 and 3 were, respectively, 48% and 18%. A total of 135 patients (46.6%) had steatosis. Liver steatosis, in multivariate analysis, was associated with hepatitis C virus genotype 3, higher grade of necroinflammation, and higher BMI. There was no significant association between stage of fibrosis and liver steatosis. In multivariate analysis, high stage of fibrosis was associated with male sex, age over 50 years, high BMI, and high grade of necroinflammation.
CONCLUSION: In our population of patients with chronic hepatitis C, steatosis does not seem to be an important determinant of liver fibrosis. High grade of necroinflammation is associated with a high stage of fibrosis.

Entities:  

Mesh:

Year:  2003        PMID: 14570735      PMCID: PMC1773870          DOI: 10.1136/gut.52.11.1638

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

1.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

Authors:  L Rubbia-Brandt; R Quadri; K Abid; E Giostra; P J Malé; G Mentha; L Spahr; J P Zarski; B Borisch; A Hadengue; F Negro
Journal:  J Hepatol       Date:  2000-07       Impact factor: 25.083

3.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.

Authors:  L E Adinolfi; M Gambardella; A Andreana; M F Tripodi ; R Utili; G Ruggiero
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

4.  Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3.

Authors:  L Rubbia-Brandt; G Leandro; L Spahr; E Giostra; R Quadri; P J Malé; F Negro
Journal:  Histopathology       Date:  2001-08       Impact factor: 5.087

5.  Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis.

Authors:  Gabriel Perlemuter; Abdelmajid Sabile; Philippe Letteron; Giovanna Vona; André Topilco; Yves Chrétien; Kazuhiko Koike; Dominique Pessayre; John Chapman; Giovanna Barba; Christian Bréchot
Journal:  FASEB J       Date:  2002-02       Impact factor: 5.191

Review 6.  Epidemiology of hepatitis C: geographic differences and temporal trends.

Authors:  A Wasley; M J Alter
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

7.  Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels.

Authors:  T Asselah; M Martinot; D Cazals-Hatem; N Boyer; A Auperin; V Le Breton; S Erlinger; C Degott; D Valla; P Marcellin
Journal:  J Viral Hepat       Date:  2002-01       Impact factor: 3.728

8.  Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis.

Authors:  Manuela G Neuman; J P Benhamou; I M Malkiewicz; A Ibrahim; D C Valla; M Martinot-Peignoux; T Asselah; M Bourliere; G G Katz; N H Shear; P Marcellin
Journal:  J Viral Hepat       Date:  2002-03       Impact factor: 3.728

9.  Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus.

Authors:  Hervé Lerat; Masao Honda; Michael R Beard; Kim Loesch; Jiaren Sun; Yan Yang; Michiari Okuda; Rainer Gosert; Shu-Yuan Xiao; Steven A Weinman; Stanley M Lemon
Journal:  Gastroenterology       Date:  2002-02       Impact factor: 22.682

10.  Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein.

Authors:  Michiari Okuda; Kui Li; Michael R Beard; Lori A Showalter; Frank Scholle; Stanley M Lemon; Steven A Weinman
Journal:  Gastroenterology       Date:  2002-02       Impact factor: 22.682

View more
  27 in total

1.  Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A.

Authors:  Yang Cheng; Sébastien Dharancy; Mathilde Malapel; Pierre Desreumaux
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

Review 2.  Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis.

Authors:  Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

Review 3.  Steatosis in chronic hepatitis C: why does it really matter?

Authors:  T Asselah; L Rubbia-Brandt; P Marcellin; F Negro
Journal:  Gut       Date:  2006-01       Impact factor: 23.059

4.  Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B.

Authors:  Fehmi Ateş; Mehmet Yalnız; Saadet Alan
Journal:  World J Gastroenterol       Date:  2011-10-28       Impact factor: 5.742

5.  Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy.

Authors:  Jose-Eymard Medeiros-Filho; Isabel-Maria-Vicente-Guedes de Carvalho Mello; Joao-Renato-Rebello Pinho; Avidan-U Neumann; Fernanda de Mello Malta; Luiz-Caetano da Silva; Flair-Jose Carrilho
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

6.  Changes in lipid metabolism in chronic hepatitis C.

Authors:  Katalin Jármay; Gizella Karácsony; András Nagy; Zsuzsa Schaff
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

7.  Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Authors:  James E Everhart; Anna S Lok; Hae-Young Kim; Timothy R Morgan; Karen L Lindsay; Raymond T Chung; Herbert L Bonkovsky; Marc G Ghany
Journal:  Gastroenterology       Date:  2009-05-13       Impact factor: 22.682

Review 8.  Hepatitis C virus infection: Are there still specific problems with genotype 3?

Authors:  Claire Gondeau; Georges Philippe Pageaux; Dominique Larrey
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 9.  Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Authors:  Amedeo Lonardo; Luigi Elio Adinolfi; Luciano Restivo; Stefano Ballestri; Dante Romagnoli; Enrica Baldelli; Fabio Nascimbeni; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

10.  Effect of liver steatosis on therapeutic response in chronic hepatitis C virus genotype 1 infected patients in hungary.

Authors:  Klara Werling; Zsuzsa Schaff; Elek Dinya; Zsolt Tulassay
Journal:  Pathol Oncol Res       Date:  2009-09-15       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.